The diagnosis of late-onset (age ≥50 years old) relapsing remitting multiple sclerosis (LORRMS) has been increasingly described in clinical practice, whereas data focusing on the specific therapeutic management of LORRMS are scarce. Our objective was to compare the effectiveness of injectable and oral first-line disease-modifying therapies (DMTs) in a cohort of LORRMS patients with time to first relapse, time to confirmed disability progression (CDP), and time to discontinuation.
First-line therapies in late-onset multiple sclerosis: An Italian registry study
Patti, Francesco;D'Amico, Emanuele
2021-01-01
Abstract
The diagnosis of late-onset (age ≥50 years old) relapsing remitting multiple sclerosis (LORRMS) has been increasingly described in clinical practice, whereas data focusing on the specific therapeutic management of LORRMS are scarce. Our objective was to compare the effectiveness of injectable and oral first-line disease-modifying therapies (DMTs) in a cohort of LORRMS patients with time to first relapse, time to confirmed disability progression (CDP), and time to discontinuation.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
First‐line therapies in late‐onset multiple sclerosis.pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Dimensione
616.64 kB
Formato
Adobe PDF
|
616.64 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
